Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States.

Prabhu, Vimalanand S; Solomkin, Joseph S; Medic, Goran; Foo, Jason; Borse, Rebekah H; Kauf, Teresa; Miller, Benjamin; Sen, Shuvayu S; Basu, Anirban

Prabhu, Vimalanand S; Solomkin, Joseph S; Medic, Goran; Foo, Jason; Borse, Rebekah H; Kauf, Teresa; Miller, Benjamin; Sen, Shuvayu S; Basu, Anirban.

Afiliação

Prabhu VS; Merck & Co., Inc., Kenilworth, NJ USA.
Solomkin JS; Center for Observational and Real World Evidence (CORE), Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033 USA.
Medic G; University of Cincinnati College of Medicine, Cincinnati, OH USA.
Foo J; Mapi Group, Houten, The Netherlands.
Borse RH; Mapi Group, Houten, The Netherlands.
Kauf T; Merck & Co., Inc., Kenilworth, NJ USA.
Miller B; Baxalta US Inc., Boston, MA USA.
Sen SS; Shire, Lexington, MA USA.
Basu A; Merck & Co., Inc., Kenilworth, NJ USA.

Antimicrob Resist Infect Control ; 6: 107, 2017.

Article em En | MEDLINE | ID: mdl-29090091

Palavras-chave

Ceftolozane; Cost-effectiveness analysis; Drug resistance; Intraabdominal infections; Piperacillin; Tazobactam; United States

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google